Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bayer
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation
The Primary efficacy objective is to compare Recurrence Free Survival (RFS) in the patients treated with sorafenib vs placebo after receiving potentially curative treatment with surgical resection or ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
Study of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus in subjects with bone predominant HER2 negative hormone receptor positive metastatic breast cancer. Estudio de dicloruro de radio-223 en combinación con exemestano y everolimús frente a placebo en combinación con exemestano y everolimús en pacientes con cáncer de mama metastásico predominante en hueso, negativo para HER2 y positivo para los receptores hormonales
The objective of this study is to assess efficacy and safety of radium 223 dichloride in combination with exemestane and everolimus in subjects with human epidermal growth factor receptor 2 (HER2) neg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
MAGELLaN - Multicenter, rAndomized, parallel Group Efficacy and safety study for the prevention of venous thromboembolism in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin
The objective of this study is to demonstrate (1) the superior efficacy of VTE prophylaxis with oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days to SC enoxaparin 40 mg once daily (OD) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Bayer Healthcare LLC
MAJ Il y a 5 ans
Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to once-a-week prophylaxis treatment and to on-demand treatment with rFVIII-FS reconstituted with water for injection in previously treated patients with severe hemophilia A
The primary objective is to evaluate the effect of a once-a-week prophylaxis regimen with BAY 79-4980 on the frequency of all bleeds compared to once-a-week prophylaxis regimen and to on-demand treatm...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer Healthcare AG, D-51368 Leverkusen, Germany
MAJ Il y a 5 ans
Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP)
El objetivo principal del programa es permitir que los pacientes que actualmente reciben monoterapia con sorafenib (Nexavar®) en un ensayo clínico patrocinado por Bayer/Onyx puedan continuar el tratam...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Lisa Bayer, MD MPH
MAJ Il y a 5 ans
Paracervical Block for Pain Control With Osmotic Dilator Placement
Cervical dilators are frequently used for preparation prior to second trimester surgical abortion. While their use decreases complications associated with surgical abortion, their placemen...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer AG
MAJ Il y a 5 ans
Managing neovascular age-related macular degeneration over 2 years using of different schedules of 2 mg aflibercept injected in the eye (ARIES)
To assess whether 2 mg IVT aflibercept administered in an early-start T&E regimen (initiated after the first 8-weekly treatment interval) is non-inferior to 2 mg IVT aflibercept administered in a late...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes (39039039ACS2001) The ATLAS ACS TIMI 46 Trial (Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome)
Stage 1 Dose Escalation The primary objective of Stage 1 (Dose Escalation) of this study is to evaluate the safety of rivaroxaban in subjects with recent acute coronary syndrome (ACS) (including ST-se...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Freistaat Bayern, represented by Universität Regensburg
MAJ Il y a 5 ans
Die Wirksamkeit einer medikamentösen Behandlung mit SOM230 LAR hinsichtlich Tumorgrößenreduktion bei Patienten mit primär inoperablem Thymom und/oder einem lokalen Thymomrezidiv
• Tumor shrinkage Response is defined as the decrease in tumor volume of 20 % at EOS as compared to baseline.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bayer HealthCare AG
MAJ Il y a 5 ans
An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma
The objective of this study is to make BAY 43-9006 available for patients with advanced RCC, who failed prior systemic therapy for advanced disease (i. e., require second line treatment), and who do n...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
17
18
19
20
21
22
23
24
25
26
Suivant